Transcode Therapeutics Net Income
| RNAZ Stock | USD 8.91 1.06 10.63% |
As of the 7th of February, Transcode Therapeutics has the Variance of 41.73, risk adjusted performance of (0.01), and Coefficient Of Variation of (4,265). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Transcode Therapeutics, as well as the relationship between them.
Transcode Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Transcode Therapeutics' valuation are provided below:We have found one hundred twenty available fundamental trend indicators for Transcode Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Transcode Therapeutics current market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 25.7 M in 2026. Enterprise Value is likely to drop to about 19.4 M in 2026 This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -15.8 M | -15 M | |
| Net Loss | -15.1 M | -14.3 M | |
| Net Loss | -15.1 M | -15.8 M | |
| Net Loss | (54.11) | (56.81) |
Transcode | Net Income | Build AI portfolio with Transcode Stock |
The evolution of Net Income for Transcode Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Transcode Therapeutics compares to historical norms and industry peers.
Latest Transcode Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Transcode Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Transcode Therapeutics financial statement analysis. It represents the amount of money remaining after all of Transcode Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Transcode Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Transcode Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (16.75 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Transcode Net Income Regression Statistics
| Arithmetic Mean | (5,655,675) | |
| Coefficient Of Variation | (130.87) | |
| Mean Deviation | 6,491,807 | |
| Median | (453,440) | |
| Standard Deviation | 7,401,846 | |
| Sample Variance | 54.8T | |
| Range | 18.1M | |
| R-Value | (0.82) | |
| Mean Square Error | 18.7T | |
| R-Squared | 0.68 | |
| Significance | 0.000046 | |
| Slope | (1,208,779) | |
| Total Sum of Squares | 876.6T |
Transcode Net Income History
Other Fundumenentals of Transcode Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Transcode Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Transcode Therapeutics is extremely important. It helps to project a fair market value of Transcode Stock properly, considering its historical fundamentals such as Net Income. Since Transcode Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Transcode Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Transcode Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Transcode Therapeutics. Anticipated expansion of Transcode directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Transcode Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of Transcode Therapeutics is measured differently than its book value, which is the value of Transcode that is recorded on the company's balance sheet. Investors also form their own opinion of Transcode Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Transcode Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Transcode Therapeutics' market value can be influenced by many factors that don't directly affect Transcode Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Transcode Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Transcode Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Transcode Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Transcode Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Transcode Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Transcode Therapeutics.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Transcode Therapeutics on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Transcode Therapeutics or generate 0.0% return on investment in Transcode Therapeutics over 90 days. Transcode Therapeutics is related to or competes with In8bio, Lyra Therapeutics, Aptevo Therapeutics, Galecto, Phio Pharmaceuticals, HCW Biologics, and Kiora Pharmaceuticals. TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and... More
Transcode Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Transcode Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Transcode Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 34.47 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 9.74 |
Transcode Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Transcode Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Transcode Therapeutics' standard deviation. In reality, there are many statistical measures that can use Transcode Therapeutics historical prices to predict the future Transcode Therapeutics' volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.80) | |||
| Treynor Ratio | (1.25) |
Transcode Therapeutics February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (1.24) | |||
| Mean Deviation | 4.46 | |||
| Coefficient Of Variation | (4,265) | |||
| Standard Deviation | 6.46 | |||
| Variance | 41.73 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (0.80) | |||
| Treynor Ratio | (1.25) | |||
| Maximum Drawdown | 34.47 | |||
| Value At Risk | (8.73) | |||
| Potential Upside | 9.74 | |||
| Skewness | 1.57 | |||
| Kurtosis | 4.03 |
Transcode Therapeutics Backtested Returns
At this stage we consider Transcode Stock to be moderately volatile. Transcode Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0171, which indicates the firm had a 0.0171 % return per unit of risk over the last 3 months. We have found twenty-two technical indicators for Transcode Therapeutics, which you can use to evaluate the volatility of the company. Please validate Transcode Therapeutics' Coefficient Of Variation of (4,265), risk adjusted performance of (0.01), and Variance of 41.73 to confirm if the risk estimate we provide is consistent with the expected return of 0.11%. Transcode Therapeutics has a performance score of 1 on a scale of 0 to 100. The entity has a beta of 0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Transcode Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Transcode Therapeutics is expected to be smaller as well. Transcode Therapeutics right now has a risk of 6.6%. Please validate Transcode Therapeutics mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and daily balance of power , to decide if Transcode Therapeutics will be following its existing price patterns.
Auto-correlation | 0.04 |
Virtually no predictability
Transcode Therapeutics has virtually no predictability. Overlapping area represents the amount of predictability between Transcode Therapeutics time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Transcode Therapeutics price movement. The serial correlation of 0.04 indicates that only as little as 4.0% of current Transcode Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.04 | |
| Spearman Rank Test | -0.36 | |
| Residual Average | 0.0 | |
| Price Variance | 2.1 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Transcode Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Transcode Therapeutics reported net income of (16.75 Million). This is 104.91% lower than that of the Biotechnology sector and 123.92% lower than that of the Health Care industry. The net income for all United States stocks is 102.93% higher than that of the company.
Transcode Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Transcode Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Transcode Therapeutics could also be used in its relative valuation, which is a method of valuing Transcode Therapeutics by comparing valuation metrics of similar companies.Transcode Therapeutics is currently under evaluation in net income category among its peers.
Transcode Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Transcode Therapeutics from analyzing Transcode Therapeutics' financial statements. These drivers represent accounts that assess Transcode Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Transcode Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 13.8B | 5.6B | 23.1M | 23.5M | 27.1M | 25.7M | |
| Enterprise Value | 13.8B | 5.6B | 20.8M | 17.8M | 20.4M | 19.4M |
Transcode Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Transcode Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Transcode Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Transcode Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Transcode Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Transcode Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Transcode Therapeutics' value.| Shares | Sabby Management Llc | 2025-06-30 | 0.0 | Warberg Asset Management Llc | 2025-06-30 | 0.0 | Corsair Capital Management Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Anson Funds Management Lp | 2025-03-31 | 1.5 M | Goldman Sachs Group Inc | 2025-06-30 | 28 K | Ubs Group Ag | 2025-06-30 | 1.4 K | Southstate Bank Corp | 2025-06-30 | 482 | Tower Research Capital Llc | 2025-06-30 | 402 | Sbi Securities Co Ltd | 2025-06-30 | 10.0 | Royal Bank Of Canada | 2025-06-30 | 8.0 |
Transcode Fundamentals
| Return On Equity | -17.63 | ||||
| Return On Asset | -2.33 | ||||
| Current Valuation | 2.09 M | ||||
| Shares Outstanding | 916.97 K | ||||
| Shares Owned By Insiders | 9.20 % | ||||
| Shares Owned By Institutions | 7.15 % | ||||
| Number Of Shares Shorted | 59.7 K | ||||
| Price To Book | 5.52 X | ||||
| EBITDA | (16.19 M) | ||||
| Net Income | (16.75 M) | ||||
| Cash And Equivalents | 13.45 M | ||||
| Cash Per Share | 1.04 X | ||||
| Total Debt | 38.29 K | ||||
| Current Ratio | 8.06 X | ||||
| Book Value Per Share | 1.71 X | ||||
| Cash Flow From Operations | (13.34 M) | ||||
| Short Ratio | 0.45 X | ||||
| Earnings Per Share | (236.52) X | ||||
| Target Price | 10.0 | ||||
| Beta | 1.56 | ||||
| Market Capitalization | 9.14 M | ||||
| Total Asset | 7.29 M | ||||
| Retained Earnings | (63.2 M) | ||||
| Working Capital | 4.32 M | ||||
| Net Asset | 7.29 M |
About Transcode Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Transcode Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transcode Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transcode Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Transcode Stock Analysis
When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.